From OCMS/SCMS with permission from AMA
In a new letter to senior diversion control officials at the Drug Enforcement Administration (DEA), the AMA is seeking important updates in the DEA rules that govern electronic prescribing of controlled substances (EPCS). Adoption of EPCS can support high-quality patient care and reduce fraud, tampering and diversion of prescription drugs, such as opioid analgesics.
The current rules, which have been unchanged since 2010, prevent user-friendly devices that are widely available in medical practices from being deployed to meet the multifactor authentication standards DEA now requires. The AMA letter outlines specific changes that are needed in the regulations for biometric devices in order to make it simpler and less expensive for physicians to adopt EPCS and have it integrated into their practice workflows.
These requests are consistent with a recommendation from the President's Commission on Combating Drug Addiction and the Opioid Crisis that the DEA should increase EPCS to prevent diversion and forgery.